#1 Clinical Trials Search in Europe

Sodium ({(2S)-1,4-Bis[2-(4-Chloro-3-Fluorophenoxy)Acetamido]Bicyclo[2.2.2]Octan-2-Yl}Oxy)Methyl Hydrogen Phosphate-2-Amino-2-(Hydroxymethyl)Propane-1,3-Diol (1/1/1)

This article discusses a clinical trial investigating the use of Fosigotifator, a new drug containing Sodium ({(2S)-1,4-Bis[2-(4-Chloro-3-Fluorophenoxy)Acetamido]Bicyclo[2.2.2]Octan-2-Yl}Oxy)Methyl Hydrogen Phosphate-2-Amino-2-(Hydroxymethyl)Propane-1,3-Diol (1/1/1), for treating Vanishing White Matter Disease (VWM). The study aims to assess the safety, tolerability, and effectiveness of this medication in both adult and pediatric patients with VWM, a rare genetic disorder affecting the brain’s white matter.

Table of Contents

What is Fosigotifator?

Fosigotifator is a new medication being studied for the treatment of Vanishing White Matter Disease (VWM). It’s also known by its scientific name, which is quite long: SODIUM ({(2S)-1,4-BIS[2-(4-CHLORO-3-FLUOROPHENOXY)ACETAMIDO]BICYCLO[2.2.2]OCTAN-2-YL}OXY)METHYL HYDROGEN PHOSPHATE-2-AMINO-2-(HYDROXYMETHYL)PROPANE-1,3-DIOL (1/1/1). The medication is also referred to as ABBV-CLS-7262 in research settings.[1]

What is Vanishing White Matter Disease?

Vanishing White Matter Disease (VWM) is a rare genetic disorder that affects the brain’s white matter. White matter is made up of nerve fibers covered by myelin, which helps messages travel quickly between different parts of the brain. In VWM, this white matter gradually disappears, leading to various neurological problems.[1]

How Fosigotifator Works

Fosigotifator is what’s called a “prodrug.” This means it’s an inactive form of the medication that becomes active once it’s in the body. The active form is known as A-1684909. Researchers are studying how this active form works in the body and brain of people with VWM disease.[1]

Current Research

A clinical trial is currently underway to study Fosigotifator. This trial is called a “Phase 1b/2 Open-label Study.” Here’s what that means:

  • Phase 1b/2: This is an early stage of testing in humans. It looks at safety and how the drug works in the body.
  • Open-label: This means both the researchers and the participants know they’re receiving the study drug.

The main goals of this study are to:[1]

  1. Check if Fosigotifator is safe and well-tolerated by people with VWM disease.
  2. Understand how the active form of the drug (A-1684909) moves through the body and brain.
  3. Look for early signs that the drug might be helping patients with VWM disease.

Who Can Participate in the Study?

The study includes both adults and children with VWM disease. Participants are divided into different groups based on age:[1]

  • Adults aged 18 and older
  • Adolescents aged 12 to less than 18 years
  • Children aged 6 to less than 12 years

To join the study, participants must have a confirmed diagnosis of VWM disease. This includes a clinical diagnosis by an experienced doctor, a genetic test confirming VWM, and brain imaging (MRI) consistent with VWM disease.[1]

Study Details

The study will last for about 100 weeks (nearly 2 years). During this time, researchers will:[1]

  • Monitor participants for any side effects
  • Perform regular health checks, including blood tests, heart tests (ECGs), and brain scans (MRIs)
  • Measure the levels of the active drug in the blood and spinal fluid
  • Assess any changes in the participants’ VWM symptoms

Potential Benefits and Risks

As this is an early-stage study, it’s not yet known if Fosigotifator will help people with VWM disease. The main purpose is to check if it’s safe and to understand how it works in the body.

Like all medications, Fosigotifator may have side effects. The researchers will closely monitor all participants for any potential problems. Some specific things they’ll watch for include:[1]

  • Changes in heart rhythm
  • Interactions with other medications
  • Effects on liver, kidney, or other organ function
  • Changes in mood or behavior

It’s important to note that participating in a clinical trial is a personal decision. If you or a loved one has VWM disease and are interested in this study, it’s best to discuss it with your doctor. They can help you understand if it might be a good option for you and can provide more information about the potential risks and benefits.

Aspect Details
Study Type Phase 1b/2 open-label study
Condition Vanishing White Matter Disease (VWM)
Drug Fosigotifator (ABBV-CLS-7262)
Participants Adults (≥18 years), Adolescents (12-17 years), Children (6-11 years)
Primary Objectives Safety, tolerability, and pharmacokinetics evaluation
Secondary Objectives Long-term safety and tolerability assessment
Key Assessments Adverse events, vital signs, ECGs, laboratory tests, physical examinations, brain MRI
Duration Up to 100 weeks (including follow-up)

FAQ

  • What is Vanishing White Matter Disease? Vanishing White Matter Disease (VWM) is a rare genetic disorder that affects the brain's white matter, causing progressive neurological deterioration. It can lead to motor difficulties, cognitive impairment, and other neurological symptoms.
  • What is Fosigotifator? Fosigotifator is an investigational drug being studied for the treatment of Vanishing White Matter Disease. It contains a complex chemical compound that researchers hope will help manage the symptoms and progression of VWM.
  • Who can participate in this clinical trial? The trial includes three age groups: adults 18 years and older, adolescents 12-17 years old, and children 6-11 years old. Participants must have a confirmed diagnosis of VWM disease and meet specific motor or cognitive criteria.
  • What are the main goals of this clinical trial? The primary objectives are to evaluate the safety and tolerability of Fosigotifator in patients with VWM disease, and to study how the drug is processed in the body (pharmacokinetics) in both blood and cerebrospinal fluid.
  • How long does the trial last? The trial includes a Safety Evaluation Period, followed by a Maintenance Dose Period and a Follow-up Period. Assessments are conducted up to Week 96, with a final follow-up at Week 100.

Ongoing Clinical Trials on Sodium ({(2S)-1,4-Bis[2-(4-Chloro-3-Fluorophenoxy)Acetamido]Bicyclo[2.2.2]Octan-2-Yl}Oxy)Methyl Hydrogen Phosphate-2-Amino-2-(Hydroxymethyl)Propane-1,3-Diol (1/1/1)

  • Study on the Safety and Effects of Fosigotifator in Adults and Children with Vanishing White Matter Disease

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

Glossary

  • Vanishing White Matter Disease (VWM): A rare genetic disorder affecting the brain's white matter, leading to progressive neurological deterioration.
  • Fosigotifator: The investigational drug being studied in this clinical trial for the treatment of VWM disease.
  • Pharmacokinetics (PK): The study of how a drug is processed by the body, including its absorption, distribution, metabolism, and excretion.
  • Cerebrospinal Fluid (CSF): A clear, colorless fluid that surrounds the brain and spinal cord, protecting them and helping to distribute nutrients.
  • Adverse Events (AEs): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Serious Adverse Events (SAEs): Adverse events that result in death, are life-threatening, require hospitalization, or cause significant disability.
  • Electrocardiogram (ECG): A test that measures the electrical activity of the heart to check for various heart conditions.
  • QT interval: A measurement on an ECG that represents the time it takes for the heart's electrical system to recharge between beats.
  • Magnetic Resonance Imaging (MRI): A medical imaging technique that uses magnetic fields and radio waves to create detailed images of organs and tissues in the body.
  • Prodrug: A medication that is administered in an inactive form and becomes active after being processed by the body.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-fosigotifator-in-adults-and-children-with-vanishing-white-matter-disease/